Celgene to be a frontrunner in the CAR-T space via Juno buy, says analyst

13 February 2018
mergers-acquisitions-big

US biotech major Celgene’s (Nasdaq: CELG) recent announcement of the  acquisition of Juno Therapeutics has put the company in a good position to be a frontrunner in the chimeric antigen receptor- T cell (CAR-T) space.

Celgene stands to benefit from Juno’s expertise and ongoing work into addressing concerns surrounding CAR-T, according to data and analytics company GlobalData.

In January 2018, Celgene announced a $9 billion cash buyout of the remaining 90% stake in Juno Therapeutics that it does not already own. This news signals a significant, albeit risky, push for Celgene in the cellular immunotherapies space, where the company sees Juno’s lead CAR-T candidate, JCAR017, bringing in $3 billion in sales, with a potential US Food and Drug Administration approval next year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology